Actively Recruiting
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Led by Guangdong Provincial People's Hospital · Updated on 2023-10-27
60
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
Sponsors
G
Guangdong Provincial People's Hospital
Lead Sponsor
C
Chipscreen Biosciences, Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
CONDITIONS
Official Title
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with acute myeloid leukemia (AML) according to WHO2016 criteria, excluding M3 subtype
- Detectable minimal residual disease (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
- 18 years of age or older
- ECOG performance status of 3 or less
- Expected lifespan of at least 3 months
- Willing to use contraceptive measures
- Signed informed consent form
You will not qualify if you...
- Allergy to the study drugs
- Gastrointestinal conditions preventing oral medication
- Active infection
- Dysfunction of vital organs
- Presence of other malignancies
- HIV infection
- Hepatitis B or C infection
- Prolonged QT interval on ECG
- Pregnant or breastfeeding women
- Participation in other clinical studies
- Considered unsuitable for participation by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
W
WENG jian yu, M.D.
CONTACT
L
Ling Wei, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here